19 research outputs found
Exposing human epithelial cells to zoledronic acid can mediate osteonecrosis of jaw: an in vitro model.
Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw?
Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jaws
Changing face of medication-related osteonecrosis of the jaw: Sheba Medical Center experience-fifteen years
Oral risk factors associated with medication-related osteonecrosis of the jaw in patients with cancer
Knowledge and attitudes of Brazilian dental students and dentists regarding bisphosphonate-related osteonecrosis of the jaw
Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers
Traitements inhibiteurs de la résorption osseuse en situation métastatique :bilan actuel et perspectives
The current main use of inhibitors of bone resorption, bisphosphonates and denosumab, is the prevention of the complications of bone metastases. Monthly infusions of zoledronic acid, the most potent bisphosphonate, decrease the complication rate of tumor-induced osteolysis by about 40%. Recent controlled double-blind phase III trials have demonstrated the superiority of denosumab against zoledronic acid to decrease skeletal morbidity in patients with bone metastases from breast or prostate cancer, and its noninferiority in a third trial including patients with other solid tumors or myeloma. The overall toxicity was similar between both compounds. It is recommended to start an inhibitor of bone resorption as soon as bone metastases are diagnosed, at least in patients with breast cancer. However, the optimal duration of therapy is unknown and we lack validated criteria to better individualize therapy and to define the place of intermittent treatments or of larger intervals between infusions. Lastly, recent studies indicate that zoledronic acid, but also clodronate, are able to reduce the risk of bone metastases and to prolong survival, at least in postmenopausal patients with breast cancer after surgery. This use of inhibitors of bone resorption in the adjuvant setting is not admitted yet although clinical practice is likely to change in the near future.SCOPUS: ar.jinfo:eu-repo/semantics/publishe